DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)
South Korea flag South Korea · Delayed Price · Currency is KRW
19,410
-330 (-1.67%)
Sep 10, 2026, 9:15 AM KST

DongKook Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
76,30166,02061,21947,17552,89650,345
Depreciation & Amortization
33,52631,71228,46221,09819,18717,358
Loss (Gain) From Sale of Assets
354.38-5,580-2,154-752.89-609.49-1,042
Asset Writedown & Restructuring Costs
966.191,848----
Loss (Gain) From Sale of Investments
3,0224,723-3,2845,8145,434-1,376
Loss (Gain) on Equity Investments
1,0193,689-2,551896.71-1,122-1,031
Stock-Based Compensation
--115.9-39.2-162.46-297.32-24.01
Provision & Write-off of Bad Debts
1,6302,019-165.02663.85223.25-713.06
Other Operating Activities
4,8768,89819,1862,2215,0343,413
Change in Accounts Receivable
-32,642-43,703-13,751-27,785-10,6643,656
Change in Inventory
-19,392-17,181-17,310-19,223-18,019-24,747
Change in Accounts Payable
23,36025,02912,56128,9544,606-1,349
Change in Unearned Revenue
149.2-378.01415.170.1--
Change in Other Net Operating Assets
-3,416-8,220-6,498-17,107-15,759163.08
Operating Cash Flow
89,75568,76076,09141,79340,90944,654
Operating Cash Flow Growth
13.84%-9.63%82.07%2.16%-8.39%-24.45%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-56,326-42,715-27,291-34,177-47,914-51,006
Sale of Property, Plant & Equipment
469.813,4232,9983,57925.3518.27
Cash Acquisitions
---31,703---13,000
Divestitures
--2,5722.03--
Sale (Purchase) of Intangibles
-2,683-3,082-3,937-5,413-4,0581,330
Investment in Securities
-14,630-34,242-5,631-21,13131,83716,655
Other Investing Activities
3,9714,9274,7474,7578,5072,220
Investing Cash Flow
-69,205-61,624-64,864-52,391-12,408-43,530

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-29,04139,57132,35812,67030,687
Long-Term Debt Issued
-12,00022,900-35,00022,500
Total Debt Issued
32,20041,04162,47132,35847,67053,187
Short-Term Debt Repaid
--44,741-45,999-21,084-57,836-10,854
Long-Term Debt Repaid
--3,876-27,618-3,049-22,248-3,114
Total Debt Repaid
-35,774-48,617-73,616-24,133-80,084-13,968
Net Debt Issued (Repaid)
-3,574-7,576-11,1468,225-32,41439,219
Issuance of Common Stock
-18,540----
Dividends Paid
-9,022-9,244-8,313-8,051-8,049-8,049
Other Financing Activities
-1,823-2,717-2,846-2,472672.13-1,437
Financing Cash Flow
-14,419-996.97-22,305-2,298-39,79229,733

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
1,118-231.7797.75-245.54-459.6150.51
Net Cash Flow
7,2485,907-10,281-13,141-11,75030,907

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
33,42826,04648,8007,616-7,005-6,352
Free Cash Flow Growth
-30.73%-46.63%540.73%---
Free Cash Flow Margin
3.41%2.81%6.01%1.04%-1.06%-1.07%
Free Cash Flow Per Share
743.80581.921090.81170.27-156.64-142.04
Levered Free Cash Flow
26,72717,05324,190-15,328-19,169-14,977
Unlevered Free Cash Flow
27,91718,35227,001-11,661-16,469-13,175

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1,8522,1663,3962,921898.192,699
Cash Income Tax Paid
22,88823,07411,33116,61411,67819,975
Change in Working Capital
-31,941-44,452-24,583-35,160-39,837-22,276